These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8364078)

  • 1. Febrile neutropenia.
    Klastersky J
    Curr Opin Oncol; 1993 Jul; 5(4):625-32. PubMed ID: 8364078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple combination antimicrobial regimen in the treatment of infections of neutropenic cancer patients.
    Casali A; Santini S; Della Giulia M; Di Lauro L; Vici P; Gionfra T; Sega FM
    J Exp Clin Cancer Res; 1997 Sep; 16(3):321-4. PubMed ID: 9387908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].
    Klastersky J
    Rev Med Brux; 1997 Oct; 18(5):323-7. PubMed ID: 9441328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
    Gupta A; Swaroop C; Agarwala S; Pandey RM; Bakhshi S
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):635-41. PubMed ID: 19684522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia.
    Jones RN
    Clin Infect Dis; 1999 Sep; 29(3):495-502. PubMed ID: 10530435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of fever in neutropenic patients.
    Bodey GP; Rolston KV
    J Infect Chemother; 2001 Mar; 7(1):1-9. PubMed ID: 11406750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutropenic infections: strategies for empirical therapy.
    Kibbler CC
    J Antimicrob Chemother; 1995 Oct; 36 Suppl B():107-17. PubMed ID: 8601537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation].
    Zikesoá E; Hnátková M; Vacková B; Jedlicková A; Klener P; Trnený M
    Cas Lek Cesk; 2006; 145(5):383-6, 388-9. PubMed ID: 16755776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of 315neutropenic febrile episodes in a cancer center].
    Dutronc H; Billhot M; Dupon M; Eghbali H; Donamaria C; Dauchy FA; Reiffers J
    Med Mal Infect; 2009 Jun; 39(6):388-93. PubMed ID: 19062208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-nephrotoxic empiric antimicrobial therapy in febrile neutropenic cancer patients.
    Kattan J; Droz JP; Ribrag V; Azab M; Boutan-Laroze A; Andremont A
    Eur J Cancer; 1992; 28A(4-5):867-70. PubMed ID: 1524911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia.
    Santhosh-Kumar CR; Ajarim DS; Harakati MS; al Momen AK; al Mohareb F; Zeitany RG
    J Infect; 1992 Jul; 25(1):11-9. PubMed ID: 1365011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Infectious complications in pediatric cancer patients].
    Lehrnbecher T; Laws HJ
    Klin Padiatr; 2005 Nov; 217 Suppl 1():S3-8. PubMed ID: 16288349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness.
    Klastersky J
    Curr Opin Oncol; 1998 Jul; 10(4):284-90. PubMed ID: 9702394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia.
    Bal AM; Gould IM
    Int J Antimicrob Agents; 2007 May; 29(5):501-9. PubMed ID: 17346939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care.
    Elting LS; Rubenstein EB; Rolston K; Cantor SB; Martin CG; Kurtin D; Rodriguez S; Lam T; Kanesan K; Bodey G
    J Clin Oncol; 2000 Nov; 18(21):3699-706. PubMed ID: 11054443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia?
    Karthaus M; Carratalà J; Jürgens H; Ganser A
    Chemotherapy; 1998; 44(6):427-35. PubMed ID: 9755304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
    Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
    Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.